

## **Supplemental Data**

### **Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis**

Daisuke Ito, MD, Atsushi Hashizume, MD, PhD, Yasuhiro Hijikata, MD, PhD, Shinichiro Yamada, MD, PhD, Yohei Iguchi, MD, PhD, Madoka Iida, MD, PhD, Yoshiyuki Kishimoto, MD, Hideyuki Moriyoshi, MD, Akihiro Hirakawa, PhD, Masahisa Katsuno, MD, PhD

#### **Contents:**

Supplemental Table 1, 2

**Supplementary Table 1. Muscle-related biomarkers in male and female subjects**

Male	Baseline			Change at 48 weeks		
	ALS	HC	p-value	ALS	HC	p-value
<b>Blood test</b>	<b>ALS (n = 25)</b>	<b>HC (n = 13)</b>		<b>ALS (n = 25)</b>	<b>HC (n = 13)</b>	
CK (U/L)	266.0 ± 269.9	111.1 ± 61.3	0.011	-81.4 ± 158.1	-4.9 ± 58.3	0.039
log CK	2.26 ± 0.39	1.99 ± 0.22	0.032	-0.16 ± 0.31	-0.02 ± 0.14	0.065
Cr (mg/dL)	0.75 ± 0.22	0.84 ± 0.15	0.199	-0.10 ± 0.15	0.03 ± 0.10	0.010
<b>Body composition</b>	<b>ALS (n = 25)</b>	<b>HC (n = 13)</b>		<b>ALS (n = 25)</b>	<b>HC (n = 13)</b>	
ALST mass (kg)	18.46 ± 3.75	21.97 ± 2.73	0.005	-2.70 ± 2.41	-0.62 ± 1.48	0.007

  

Female	Baseline			Change at 48 weeks		
	ALS	HC	p-value	ALS	HC	p-value
<b>Blood test</b>	<b>ALS (n = 14)</b>	<b>HC (n = 7)</b>		<b>ALS (n = 14)</b>	<b>HC (n = 7)</b>	
CK (U/L)	147.4 ± 61.9	100.6 ± 38.5	0.084	-69.2 ± 92.3	15.3 ± 26.8	0.006
log CK	2.13 ± 0.19	1.97 ± 0.18	0.075	-0.24 ± 0.30	0.05 ± 0.14	0.006
Cr (mg/dL)	0.56 ± 0.10	0.64 ± 0.06	0.060	-0.08 ± 0.14	0.01 ± 0.03	0.032
<b>Body composition</b>	<b>ALS (n = 14)<sup>a</sup></b>	<b>HC (n = 7)</b>		<b>ALS (n = 10)</b>	<b>HC (n = 7)</b>	
ALST mass (kg)	13.4 ± 1.8	14.1 ± 1.5	0.412	-2.20 ± 1.96	-0.04 ± 0.36	0.012

<sup>a</sup>Longitudinal data of body compositions was not available in 4 subjects with ALS.

ALS, amyotrophic lateral sclerosis; ALST, appendicular lean soft tissue; CK, creatine kinase; Cr, creatinine; HC, healthy control. Data represent mean ± standard deviation.

**Supplementary Table 2. Correlation between ALSFRS-R and each parameter**

	Correlation between baseline values and baseline ALSFRS-R		Correlation between annualized changes and $\Delta$ ALSFRS-R	
	r	p-value	r	p-value
<b>Blood test</b>	<b>ALS (n = 39)</b>		<b>ALS (n = 39)</b>	
CK (U/L)	0.233	0.154	0.327	0.042
log CK	0.371	0.020	0.427	0.007
Cr (mg/dL)	-0.018	0.914	0.456	0.004
CysC (mg/L)	-0.327	0.042	0.141	0.399
UN (mg/dL)	-0.229	0.160	0.201	0.220
UA (mg/dL)	-0.221	0.176	-0.021	0.900
AST (U/L)	0.062	0.709	0.179	0.274
ALT (U/L)	-0.078	0.638	0.359	0.025
T-Bil (mg/dL)	0.087	0.613	0.083	0.629
ALP (U/L)	-0.107	0.517	0.129	0.441
$\gamma$ -GTP (U/L)	-0.163	0.321	-0.005	0.974
TP (g/dL)	0.182	0.269	0.262	0.108
Alb (g/dL)	0.341	0.034	0.144	0.382
LDH (U/L)	0.424	0.007	0.337	0.039
LDL-C (mg/dL)	0.111	0.507	0.004	0.980
HDL-C (mg/dL)	0.266	0.107	0.154	0.362
HbA1c (%)	-0.341	0.034	0.451	0.005
WBC ( $10^3/\mu$ L)	0.028	0.864	-0.790	0.633
Hb (g/dL)	0.042	0.801	-0.052	0.753
Plt ( $10^3/\mu$ L)	0.120	0.467	-0.197	0.228
<b>Body composition</b>	<b>ALS (n = 39)<sup>a</sup></b>		<b>ALS (n = 35)</b>	
ALST mass (kg)	-0.069	0.677	0.381	0.024
BMC (kg)	-0.138	0.403	0.436	0.009
Total fat mass(kg)	-0.084	0.613	0.562	<0.001

<sup>a</sup>Longitudinal data of body compositions was not available in 4 subjects with ALS.

Alb, albumin; ALP, alkaline phosphatase; ALS, amyotrophic lateral sclerosis; ALST, appendicular lean soft tissue; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMC, bone mineral content; CK, creatine kinase; Cr, creatinine; CysC, cystatin C;  $\gamma$ -GTP, gamma glutamyl transpeptidase; Hb, hemoglobin; HbA1c, hemoglobin A1c; HC, healthy control; HDL-C, high-density lipoprotein cholesterol; LDH, lactate dehydrogenase; LDL, low-density lipoprotein

cholesterol; Plt, platelet count; T-Bil, total bilirubin; TP, total protein; UA, uric acid; UN, uric nitrate; WBC, white blood cell count. Data represent mean  $\pm$  standard deviation.